IL248318A0 - Selective inhibitors that have an effect on the hepatitis virus type c - Google Patents

Selective inhibitors that have an effect on the hepatitis virus type c

Info

Publication number
IL248318A0
IL248318A0 IL248318A IL24831816A IL248318A0 IL 248318 A0 IL248318 A0 IL 248318A0 IL 248318 A IL248318 A IL 248318A IL 24831816 A IL24831816 A IL 24831816A IL 248318 A0 IL248318 A0 IL 248318A0
Authority
IL
Israel
Prior art keywords
hepatitis
potent
virus
selective inhibitors
inhibitors
Prior art date
Application number
IL248318A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Emory
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Cocrystal Pharma Inc filed Critical Univ Emory
Publication of IL248318A0 publication Critical patent/IL248318A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL248318A 2014-04-15 2016-10-13 Selective inhibitors that have an effect on the hepatitis virus type c IL248318A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
IL248318A0 true IL248318A0 (en) 2016-11-30

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248318A IL248318A0 (en) 2014-04-15 2016-10-13 Selective inhibitors that have an effect on the hepatitis virus type c

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101492672B1 (ko) * 2008-02-13 2015-02-16 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
CA2751458C (en) * 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112013004520A2 (pt) * 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
MX2013004906A (es) * 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Also Published As

Publication number Publication date
SG11201608587QA (en) 2016-11-29
RU2016144076A (ru) 2018-05-16
KR20170002407A (ko) 2017-01-06
CA2945514A1 (en) 2015-10-22
JP2017513852A (ja) 2017-06-01
WO2015160907A2 (en) 2015-10-22
US20170029407A1 (en) 2017-02-02
EP3131892A2 (en) 2017-02-22
EP3131892A4 (en) 2017-09-20
BR112016023833A2 (pt) 2017-10-10
MX2016013434A (es) 2017-03-03
WO2015160907A3 (en) 2016-12-01
AU2015247706A1 (en) 2016-10-27
PH12016502039A1 (en) 2017-01-09
US9926295B2 (en) 2018-03-27
CN106661004A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
IL276946A (en) Antiproliferative compounds and methods of use
IL251450A0 (en) Preparations and methods for silencing hepatitis b virus gene expression
IL250415B (en) Antibodies against pd-l and methods of using them
SG10201912085WA (en) Anti-cd33 antibodies and methods of use thereof
ZA201608885B (en) Process and device for desulfurization-denitration of flue gas
EP3240787A4 (en) Derivatives and methods of treating hepatitis b infections
SG11201703569XA (en) HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
SG11201605649TA (en) Azepane derivatives and methods of treating hepatitis b infections
SG11201803213XA (en) Glycan-interacting compounds and methods of use
PL3089971T3 (pl) Związki i sposoby ich zastosowania
IL252560A0 (en) Heterocyclic derivatives and their uses
GB201514760D0 (en) Compounds and method of use
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
IL254243B (en) Hepatitis C virus polymerase inhibitors.
PL3137078T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu delta
SG11201608587QA (en) Potent and selective inhibitors of hepatitis c virus
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
IL249086A0 (en) nampt inhibitors and methods
PL3188986T3 (pl) Opakowanie wyrobów do palenia
GB201402169D0 (en) Viral inhibitors
PL2942121T3 (pl) Tłumik środkowy i sposób wytwarzania tłumika środkowego
ZA201703123B (en) Combination long acting compositions and methods for hepatitis c
GB201403697D0 (en) Compounds and methods of use
GB201416797D0 (en) Contianer and method of use thereof